Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 6, 2006, Pages 826-834

  Bram, Eran ^a   Ifergan, Ilan ^a   Shafran, Assaf ^a   Berman, Bluma ^a   Jansen, Gerrit ^b   Assaraf, Yehuda G ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABC transporter; Chemotherapy; Drug resistance; Efflux; Lipophilic antifolates

Indexed keywords

AG 377; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLIC ACID ANTAGONIST; GLYCINE; KO 143; METESIND GLUCURONATE; METODICLOROFEN; MUTANT PROTEIN; NOLATREXED; PACLITAXEL; PIRITREXIM; PROTEIN INHIBITOR; PYRIMETHAMINE; THREONINE; TRIMETREXATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL MEMBRANE TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPID BILAYER; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; FOLIC ACID ANTAGONISTS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INDOLES; LIPIDS; MOLECULAR STRUCTURE; MUTATION; NEOPLASM PROTEINS; PACLITAXEL; PYRIMETHAMINE; PYRIMIDINES; QUINAZOLINES; TRANSFECTION; TRIMETREXATE;

EID: 33748451835     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0230-9     Document Type: Article

References (35)

1. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
2. Dean M, Harmon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007-1017
3. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485
4. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
5. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7535-7552
6. Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-53
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD (1998) A multidrug resistance transporter from MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670
8. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339
9. Miyake K, Mickley L, Litman T, Zhan Z, Robey RW, Christensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE (1999) Molecular cloning of cDNAs which are highly over-expressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13
10. Sarkadi B, Ozvegy-Laczka O, Nemet K, Varadi A (2004) ABCG2 - a transporter for all seasons. FEBS Lett 567:116-120
11. Staud F, Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720-725
12. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y (2002) Dominant-negative inhibition of breast cancer resistance protein as a drug efflux pump through the inhibition of S-S dependent dimerization. Int J Cancer 97:626-630
13. Xu J, Liu Y, Yang Y, Bates SE, Zhang JT (2004) Characterization of oligomeric human half-ABCC transporter ATP-binding cassette G2. J Biol Chem 279:19781-19789
14. Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE (2004) Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43:9448-9456
15. Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG (2005) ABCG2 harboring the Gly482 mutation confers high level resistance to hydrophilic antifolates. Cancer Res 65:8414-8422
16. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Kooman GJ, Schinkel AH (2002) Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425
17. Duch DS, Edelstein MP, Bowers SW, Nichol CA (1982) Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5- methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res 42:3987-3994
18. Fry DW, Besserer JA (1988) Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986-6991
19. Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5-14
20. Assaraf YG, Molina A, Schimke RT (1989) Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug resistance phenotype. J Natl Cancer Inst 81:290-294
21. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG (2002) Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cells. Biochem J 367:741-750
22. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG (2003) Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 103:587-599
23. Purcell WT, Ettinger DS (2003) Novel antifolate drugs. Curr Oncol Rep 5:114-125
24. Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52:S80-S89
25. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978
26. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G (1995) Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471
27. Taylor CW, Dalton WS, Parrish PR et al (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF-7 human breast cancer cell line. Br J Cancer 63:923-929
28. Ifergan I, Shafran A, Jansen G, Hooijberg JH, Scheffer GL, Assaraf YG (2004) Folate deprivation results in the loss of breast cancer resistance protein (ABCG2) expression: a role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527-25534
29. Hansch C, Hoekman D, Leo A, Zhang L, Li P (1995) The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79:45-53
30. Borgnia MJ, Eytan GD, Assaraf YG (1996) Competition of hydrophobic peptides, cytotoxic drugs and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163-3171
31. Assaraf YG, Molina A, Schimke RT (1989) Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J Biol Chem 264:18326-18334
32. Volk EL, Schneider E (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-5543
33. Chen Z-S, Robey RW, Belinsky MG, Schvaveleva I, Ren XO, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048-4054
34. Gombar VK, Polli JW, Humphreys JW, Wring AW, Serabjit-Singh CS (2004) Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 93:957-968
35. Eytan GD, Regev R, Oren G, Hurwitz C, Assaraf YG (1997) Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248:104-112